Mainz Biomed (NASDAQ:MYNZ) Upgraded by Wall Street Zen to Hold Rating

Mainz Biomed (NASDAQ:MYNZ) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $14.00.

Mainz Biomed Trading Up 8.5%

NASDAQ:MYNZ opened at $1.27 on Friday. The firm has a market capitalization of $10.90 million, a P/E ratio of -0.02 and a beta of 0.27. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.52 and a quick ratio of 0.43. Mainz Biomed has a one year low of $0.92 and a one year high of $8.20. The company’s 50-day simple moving average is $1.25 and its 200 day simple moving average is $1.51.

Mainz Biomed (NASDAQ:MYNZ) last released its earnings results on Friday, September 26th. The company reported ($1.32) earnings per share (EPS) for the quarter. The firm had revenue of $0.14 million for the quarter. As a group, analysts forecast that Mainz Biomed will post -23.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Mainz Biomed

An institutional investor recently raised its position in Mainz Biomed stock. Armistice Capital LLC boosted its holdings in Mainz Biomed NV (NASDAQ:MYNZ) by 38.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 394,519 shares of the company’s stock after acquiring an additional 109,519 shares during the quarter. Armistice Capital LLC owned 7.29% of Mainz Biomed worth $588,000 at the end of the most recent quarter.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.